January 23, 2025 - 12:24

Robert F. Kennedy Jr., nominated by President Trump to lead the Department of Health and Human Services (HHS), is scheduled to testify before the Senate Finance Committee on January 29. This hearing is a crucial step in the confirmation process, as Kennedy seeks to outline his vision for health policy and address pressing issues facing the department.
Kennedy, a prominent environmental attorney and vaccine skeptic, has garnered both support and opposition regarding his nomination. His views on public health and environmental concerns are expected to be central topics during the hearing. Senators will likely question him on his stance toward vaccine policies, healthcare access, and the ongoing challenges posed by the COVID-19 pandemic.
The outcome of this hearing could significantly influence Kennedy's confirmation, as committee members assess his qualifications and readiness to lead such a vital federal agency. As the date approaches, all eyes will be on Kennedy and his responses to the committee's inquiries.
March 17, 2026 - 05:46
Virginia joins multi-state lawsuit against OneMain FinancialVirginia has officially joined a coalition of a dozen states in filing a lawsuit against OneMain Financial, a major consumer loan company. The legal action, announced by Attorney General Jay Jones,...
March 16, 2026 - 02:28
Barclays Lifts PT on EOG Resources (EOG) to $140 From $133In a recent move underscoring confidence in the energy sector, investment bank Barclays has increased its price target for EOG Resources, Inc. The firm lifted its target to $140 per share, up from...
March 15, 2026 - 05:53
Peak War Panic Predicted to Grip Markets Within WeeksA leading market strategist warns that global financial markets are likely to experience a peak period of war-induced panic within the next one to three weeks. This forecast comes as both the...
March 14, 2026 - 22:13
A Look At Afya (NasdaqGS:AFYA) Valuation After Recent Mixed Share Price PerformanceThe valuation of Brazilian medical education leader Afya is under scrutiny following a period of mixed performance for its shares. While the stock experienced a modest single-day gain of...